A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 10,825 shares of CADL stock, worth $49,578. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,825
Holding current value
$49,578
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.02 - $7.76 $54,341 - $84,002
10,825 New
10,825 $75,000

Others Institutions Holding CADL

About Candel Therapeutics, Inc.


  • Ticker CADL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,891,900
  • Market Cap $132M
  • Description
  • Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...
More about CADL
Track This Portfolio

Track Mirae Asset Global Etfs Holdings Ltd. Portfolio

Follow Mirae Asset Global Etfs Holdings Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Etfs Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Etfs Holdings Ltd. with notifications on news.